Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Inactivated Poliomyelitis vaccine (IMOVAX), IMOVAX Polio™ (IPV)
Inactivated Poliomyelitis vaccine · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| Group 1 | EXPERIMENTAL | Children at 18 months of age |
| Group 2 | EXPERIMENTAL | Infants at 2 months of age |
| Group A | EXPERIMENTAL | - |
| Group B | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Inactivated Poliomyelitis vaccine | BIOLOGICAL | 0.5 mL, intramuscular (IM) |
| Inactivated Poliomyelitis vaccine (IMOVAX) | BIOLOGICAL | Fractional dose (1/5th) 0.1 mL, intradermally |
Inclusion Criteria: * Group 1: Aged 18 months (18-20 months) on the day of inclusion * Group 2: Aged 2 months (56-70 days) on the day of inclusion Exclusion Criteria: * Participation in another clinical trial in the 4 weeks preceding the trial vaccination * Planned participation in another clinic...
Inactivated Poliomyelitis vaccine is used to prevent poliomyelitis, a viral disease that can cause paralysis. It is given as a vaccine to healthy infants and children, and the clinical trials supporting it enrolled participants from 42 days of age. The product is marketed under the name IMOVAX.
Sanofi develops and manufactures the Inactivated Poliomyelitis vaccine, which is marketed as IMOVAX. Sanofi trades on the New York Stock Exchange under the ticker SNY. The vaccine is part of Sanofi's infectious disease portfolio.
The Inactivated Poliomyelitis vaccine is in Phase 3 clinical development. Two trials have been completed, including a Phase 3 safety study in Chinese infants and children and a Phase 2 immunogenicity study. No trials are currently active.
Two completed trials studied the Inactivated Poliomyelitis vaccine. NCT00604058 was a Phase 2 trial in the Philippines comparing fractional intradermal doses with full intramuscular doses in 236 participants. NCT00258843 was a Phase 3 safety trial of IMOVAX in 40 Chinese infants and children.
Yes, IMOVAX is the brand name for Sanofi's Inactivated Poliomyelitis vaccine. The two names refer to the same vaccine product, and the Phase 3 trial NCT00258843 was conducted under the IMOVAX name in Chinese infants and children.
Trials of the Inactivated Poliomyelitis vaccine have used active-controlled, randomized designs. NCT00604058 compared fractional intradermal doses against full intramuscular doses, while NCT00258843 evaluated safety in Chinese infants and children. Together the two completed studies enrolled 276 participants.